Literature DB >> 3889275

Nasal delivery of polypeptides I: nasal absorption of enkephalins in rats.

K S Su, K M Campanale, L G Mendelsohn, G A Kerchner, C L Gries.   

Abstract

The serum levels of two enkephalins after various routes of administration were compared in rats. The results indicated that serum levels of metkephamid after nasal administration were not significantly different than levels after intravenous injection. The oral administration of metkephamid resulted in undetectable serum levels. The effects of a promoter and variations in the peptide dose on nasal absorption were studied. Depending on the stability of the polypeptide and its susceptibility to enzymatic degradation, nasal absorption of peptides can be influenced by the presence of a promoting agent in the formulation. A linear relationship between the dose and the AUC was observed in the range of concentrations studied. The absorption mechanism appears to be passive diffusion. Microscopic examinations of nasal mucosa in rats revealed degrees of irritation which, considering the experimental exposure, were slight and probably repairable. The data indicate that enkephalins can be absorbed through the nasal mucosa into the systemic circulation, and the onset of absorption was rapid. Nasal administration may offer an attractive alternative for the delivery of proteins and/or polypeptides which are, in general, absorbed poorly when given orally.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3889275     DOI: 10.1002/jps.2600740406

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Improvements in the selective perception and training of rats using an original analog of the C-terminal fragment of vasopressin.

Authors:  N S Ponomareva; O G Voskresenskaya; A A Kamenskii; V P Golubovich; I P Ashmarin
Journal:  Neurosci Behav Physiol       Date:  2000 Mar-Apr

Review 2.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

3.  Pharmacodynamics and biophasic drug levels of methionine enkephalin.

Authors:  R J Erb; L M Her; A Abdallah; A K Mitra
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

4.  Model of disposition of drugs administered into the human nasal cavity.

Authors:  I Gonda; E Gipps
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

5.  The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats.

Authors:  S C Raehs; J Sandow; K Wirth; H P Merkle
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

6.  Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid.

Authors:  P Langguth; H P Merkle; G L Amidon
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

7.  Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations.

Authors:  T T Kararli; T E Needham; G Schoenhard; D A Baron; R E Schmidt; B Katz; B Belonio
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

8.  In vitro tolerability of human nasal mucosa: histopathological and scanning electron-microscopic evaluation of nasal forms containing Sandostatin.

Authors:  A de Fraissinette; M Kolopp; I Schiller; G Fricker; C Gammert; A Pospischil; J Vonderscher; F Richter
Journal:  Cell Biol Toxicol       Date:  1995-10       Impact factor: 6.691

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.